What cell therapies will Imviva Biotech present at ASH?

Imviva Biotech will present its allogeneic cell therapy candidates, including CAR-T therapies CTD402 and CTA311, at the ASH Annual Meeting.

What conditions do Imviva's CAR-T therapies target?

Imviva's CAR-T therapies, CTD402 and CTA311, are targeted for severe aplastic anemia and acute lymphoblastic leukemia.

What is Imviva's ANSWER platform?

The ANSWER platform is Imviva's proprietary technology designed to address limitations in current autologous and allogeneic CAR-T cell therapies.

Home / Health / Imviva Biotech Unveils Cancer Cell Therapy Breakthroughs

Imviva Biotech Unveils Cancer Cell Therapy Breakthroughs

25 Nov

•

Summary

Imviva Biotech will present advanced allogeneic cell therapies.
Presentations include CAR-T therapies for leukemia and anemia.
Company will highlight its proprietary ANSWER platform at ASH meeting.

Imviva Biotech Unveils Cancer Cell Therapy Breakthroughs

Imviva Biotech is poised to make significant waves at the 67th American Society of Hematology (ASH) Annual Meeting. The company will feature its cutting-edge allogeneic cell therapy candidates across multiple oral and poster presentations, detailing progress in treatments for serious blood disorders.

The focus will be on Imviva's CAR-T cell therapies, including CTD402 and CTA311, which are being developed for conditions such as severe aplastic anemia and acute lymphoblastic leukemia. These therapies represent a crucial step forward in combating these challenging hematological conditions.

Furthermore, Imviva will spotlight its proprietary ANSWER platform, designed to overcome existing obstacles in both autologous and allogeneic CAR-T cell therapy. The company's Chief Medical Officer expressed enthusiasm for sharing the platform's depth and breadth, emphasizing the breakthrough progress of CTD402 in leukemia treatment.